midodrine and Electrolytes studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)

Research Excerpts

Excerpt	Relevance	Reference
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."	6.69	Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."	2.69	Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
"In the OI spectrum, postural tachycardia syndrome (POTS) accounted for 826 cases (39."	1.72	[A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children]. ( Chen, YH; Cui, YX; DU, JB; Jin, HF; Liao, Y; Liu, P; Liu, XQ; Qi, JG; Sun, CF; Sun, Y; Wang, YL; Xu, WR; Yan, H; Zhang, CY; Zhang, QY, 2022)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Development of Post-paracentesis Circulatory Dysfunction (PCD)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors	Studies
Cui, YX	1
DU, JB	1
Zhang, QY	1
Liao, Y	1
Liu, P	1
Wang, YL	1
Qi, JG	1
Yan, H	1
Xu, WR	1
Liu, XQ	1
Sun, Y	1
Sun, CF	1
Zhang, CY	1
Chen, YH	1
Jin, HF	1
Angeli, P	1
Volpin, R	1
Gerunda, G	1
Craighero, R	1
Roner, P	1
Merenda, R	1
Amodio, P	1
Sticca, A	1
Caregaro, L	1
Maffei-Faccioli, A	1
Gatta, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355]	Phase 4	29 participants (Actual)	Interventional	2003-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis

Time to Recurrence of Ascites.

Intervention	participants (Number)
Albumin (Control Group)	2
Vasoconstrictor (Treatment Group)	2

Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days

midodrine and Electrolytes